amifostine anhydrous has been researched along with Adenocarcinoma in 24 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-nine patients with localized prostate cancer were accrued." | 2.70 | Intrarectal application of amifostine for the prevention of radiation-induced rectal injury. ( Ben-Josef, E; Biggar, S; Han, S; Kaplan, I; Kelly, L; Stamos, B; Tobi, M; Vargas, BJ, 2002) |
| "Patients with localized prostate cancer received amifostine as a rectal suspension 30-45 minutes before daily three-dimensional conformal radiation therapy." | 1.35 | Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score. ( Albert, PS; Camphausen, K; Coleman, CN; Cooley-Zgela, T; Crouse, NS; Godette, D; Guion, P; Ménard, C; Sciuto, LC; Simone, NL; Singh, AK; Smith, S; Soule, BP, 2008) |
| "Twenty-nine patients with localized prostate cancer were accrued." | 1.31 | A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury. ( Ben-Josef, E; Biggar, S; Bonner, HS; Han, S; Kaplan, I; Kelly, L; Prokop, S; Shaw, LM; Stamos, B; Tobi, M; Vargas, BJ, 2002) |
| "Cysteamine treatment increased the development of ER-negative tumors." | 1.31 | Inhibitory effects of WR-2721 and cysteamine on tumor initiation in mammary glands of pregnant rats by radiation. ( Inano, H; Kobayashi, H; Onoda, M; Suzuki, K; Wakabayashi, K, 2000) |
| " Both amifostine and WR 1065 were rapidly cleared from the plasma (95% and 50% of the peak concentration within 1 h, respectively)." | 1.29 | Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient. ( Gall, HE; Korst, AE; van der Vijgh, WJ; Vermorken, JB, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (16.67) | 18.7374 |
| 1990's | 4 (16.67) | 18.2507 |
| 2000's | 14 (58.33) | 29.6817 |
| 2010's | 1 (4.17) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Auttara-Atthakorn, A | 1 |
| Sungmala, J | 1 |
| Anothaisintawee, T | 1 |
| Reutrakul, S | 1 |
| Sriphrapradang, C | 1 |
| Bouhadjari, N | 1 |
| Gabato, W | 1 |
| Calabrese, D | 1 |
| Msika, S | 1 |
| Keita, H | 1 |
| Berry, E | 1 |
| Matthews, KS | 1 |
| Singh, DK | 1 |
| Buttin, BM | 1 |
| Lurain, JR | 1 |
| Alvarez, RD | 1 |
| Schink, J | 1 |
| Ben-Josef, E | 3 |
| Han, S | 2 |
| Tobi, M | 2 |
| Shaw, LM | 1 |
| Bonner, HS | 1 |
| Vargas, BJ | 2 |
| Prokop, S | 1 |
| Stamos, B | 2 |
| Kelly, L | 2 |
| Biggar, S | 2 |
| Kaplan, I | 2 |
| Myerson, R | 2 |
| Zobeiri, I | 1 |
| Birnbaum, E | 1 |
| Dietz, D | 1 |
| Fleshman, J | 1 |
| Kodner, I | 1 |
| Picus, J | 1 |
| Ratkin, G | 1 |
| Ménard, C | 2 |
| Camphausen, K | 2 |
| Muanza, T | 1 |
| Sears-Crouse, N | 1 |
| Smith, S | 2 |
| Coleman, CN | 2 |
| Scudder, SA | 1 |
| Liu, PY | 1 |
| Wilczynski, SP | 1 |
| Smith, HO | 1 |
| Jiang, C | 1 |
| Hallum, AV | 1 |
| Smith, GB | 1 |
| Hannigan, EV | 1 |
| Markman, M | 1 |
| Alberts, DS | 1 |
| Mazeron, JJ | 1 |
| Simone, NL | 1 |
| Soule, BP | 1 |
| Albert, PS | 1 |
| Guion, P | 1 |
| Godette, D | 1 |
| Crouse, NS | 1 |
| Sciuto, LC | 1 |
| Cooley-Zgela, T | 1 |
| Singh, AK | 1 |
| Yuhas, JM | 1 |
| Begg, AC | 2 |
| Terry, NH | 2 |
| Wadler, S | 1 |
| Beitler, JJ | 1 |
| Rubin, JS | 1 |
| Haynes, H | 1 |
| McGill, F | 1 |
| Rozenblit, A | 1 |
| Goldberg, G | 1 |
| Cohen, C | 1 |
| Speyer, J | 1 |
| Runowicz, C | 1 |
| Korst, AE | 1 |
| Gall, HE | 1 |
| Vermorken, JB | 1 |
| van der Vijgh, WJ | 1 |
| Vacha, P | 1 |
| Marx, M | 1 |
| Engel, A | 1 |
| Richter, E | 1 |
| Feyerabend, T | 1 |
| Inano, H | 1 |
| Onoda, M | 1 |
| Suzuki, K | 1 |
| Kobayashi, H | 1 |
| Wakabayashi, K | 1 |
| Gridelli, C | 1 |
| Guida, C | 1 |
| Barletta, E | 1 |
| Gatani, T | 1 |
| Fiore, F | 1 |
| Barzelloni, ML | 1 |
| Rossi, A | 1 |
| de Bellis, M | 1 |
| D'Aniello, R | 1 |
| Scognamiglio, F | 1 |
| Blohmer, JU | 1 |
| Paepke, S | 1 |
| Böhmer, D | 1 |
| Ernhardt, B | 1 |
| Sehouli, J | 1 |
| Elling, D | 1 |
| Lichtenegger, W | 1 |
| Yavuz, AA | 1 |
| Aydin, F | 1 |
| Yavuz, MN | 1 |
| Ilis, E | 1 |
| Ozdemir, F | 1 |
| Delioukina, ML | 1 |
| Prager, D | 1 |
| Parson, M | 1 |
| Hecht, JR | 1 |
| Rosen, P | 1 |
| Rosen, LS | 1 |
| Kligerman, MM | 1 |
| Liu, T | 1 |
| Liu, Y | 1 |
| Scheffler, B | 1 |
| He, S | 1 |
| Zhang, Z | 1 |
| Niibe, H | 1 |
| Takahashi, I | 1 |
| Mitsuhashi, N | 1 |
| Miyaishi, K | 1 |
| Itoh, J | 1 |
| Maehara, Y | 1 |
| Nakajima, N | 1 |
| Suto, H | 1 |
| Sakaino, K | 1 |
| Matsuura, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Amifostine as a Rectal Protector During External Beam Radiotherapy for Prostate Cancer: A Phase II Study[NCT00040365] | Phase 2 | 30 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
| Phase II Trial of Paclitaxel and Carboplatin With Amifostine in Advanced Recurrent or Refractory Endometrial Adenocarcinoma[NCT00003127] | Phase 2 | 57 participants (Actual) | Interventional | 1998-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The EPIC bowel assessment is a 26 item short form evaluation that assess patient function and bother after prostate treatment. The Expanded Prostate Cancer Index Composite is a self assessment questionnaire designed to measure quality of life in patients with prostate cancer. The questionnaire is scored on a scale of 0-100 with higher scores correlated with higher function and quality of life. For this study, the Bowel Domain was analyzed alongside the RTOG acute and late gastrointestinal morbidity scores. For details re: EPIC, see http://www.med.umich.edu/urology/research/EPIC/EPIC-2.2002.pdf (NCT00040365)
Timeframe: 18 months
| Intervention | scores on a scale (Mean) |
|---|---|
| Amifostine | 0.6 |
Proctoscopic scoring of mucosal change was performed according to a descriptive scale, described by Wachter et al, which assigns grades of mucosal congestion, telangiectasia, ulcerations, stricture, and necrosis. (NCT00040365)
Timeframe: 3 years
| Intervention | Participants (Number) |
|---|---|
| Amifostine | 30 |
Here are the number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00040365)
Timeframe: 3 years
| Intervention | Participants (Number) |
|---|---|
| Amifostine | 30 |
A good toxicity outcome is defined as having less than grade 2 on both weeks 5 and 7 of treatment. The Radiation Therapy Oncology Group (RTOG) Acute radiation morbidity scoring scheme and the Rectal Mucosal Toxicity response criteria will be used to assess rectal toxicity. The RTOG measures the rectal toxicities. The physician assigns a grade based on symptoms reported by the patient. For details about the RTOG (method and scoring of radiation morbidity, etc.) see http://www.rtog.org/ResearchAssociates/AdverseEventReporting/AcuteRadiationMorbidityScoringCriteria.aspx (NCT00040365)
Timeframe: RTOG Acute was used on week 5 and 7
| Intervention | Percentage of Participants (Number) |
|---|---|
| Amifostine | 20.69 |
A good toxicity outcome is defined as having less than grade 2 on both weeks 5 and 7 of treatment. Week 5, 7 were during treatment measuring acute toxicity. The Radiation Therapy Oncology Group (RTOG) Acute radiation morbidity scoring scheme and the Rectal Mucosal Toxicity response criteria will be used to assess rectal toxicity. The RTOG measures the rectal toxicities. The physician assigns a grade based on symptoms reported by the patient. For details about the RTOG see http://www.rtog.org/ResearchAssociates/AdverseEventReporting/AcuteRadiationMorbidityScoringCriteria.aspx. (NCT00040365)
Timeframe: The late rectal toxicity has been assessed at 1, 3, 6, 12, 18, 24, 36, and 60 months after the completion of treatment.
| Intervention | Percentage of Participants (Number) |
|---|---|
| Amifostine | 83.33 |
Radiation toxicity consists of the Radiation Therapy Oncology Group(RTOG)acute(within 90 days of treatment)and RTOG late(>90days after treatment). This scoring system assigns a toxicity grade (0-4) based on symptoms with 0 being the best outcome. The Expanded Prostate Cancer Index Composite(EPIC) questionnaire consists of 50 quality of life items divided into 4 domains, urinary, bowel, sexual and hormonal. Each independent domain renders a scoring of 0-100 with 100 being the best score. The EPIC and RTOG scores were correlated not combined. (NCT00040365)
Timeframe: Baseline, week 5, 7 , and months 1, 3, 6, 12, and 18
| Intervention | scores on a scale (Mean) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline bowel function | Baseline bowel bother | Week 5 bowel function | Week 5 bowel bother | Week 5 RTOG | Week 7 bowel function | Week 7 bowel bother | Week 7 RTOG | 1 month bowel function | 1 month bowel bother | 1 month RTOG | 3 month bowel function | 3 month bowel bother | 3 month RTOG | 6 month bowel function | 6 month bowel bother | 6 month RTOG | 12 month bowel function | 12 month bowel bother | 12 month RTOG | 18 month bowel function | 18 month bowel bother | 18 month RTOG | |
| Amifostine | 91.13 | 92.86 | 71.43 | 67.33 | 1.06 | 69.76 | 66.38 | 1.00 | 84.09 | 78.08 | 0.59 | 79.08 | 82.78 | 0.54 | 85.46 | 81.86 | 0.39 | 83.92 | 77.65 | 0.50 | 83.55 | 76.28 | 0.64 |
1 review available for amifostine anhydrous and Adenocarcinoma
| Article | Year |
|---|---|
Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials.
Topics: Adenocarcinoma; Amifostine; Bethanechol; Humans; Iodine Radioisotopes; Pilocarpine; Randomized Contr | 2022 |
12 trials available for amifostine anhydrous and Adenocarcinoma
| Article | Year |
|---|---|
Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
Topics: Adenocarcinoma; Amifostine; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytoprotecti | 2002 |
Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results.
Topics: Adenocarcinoma; Administration, Rectal; Aged; Amifostine; Humans; Male; Middle Aged; Prostatic Neopl | 2003 |
Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Combine | 1993 |
[Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, | 1999 |
Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study.
Topics: Adenocarcinoma; Aged; Amifostine; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; | 2000 |
[Adjuvant chemotherapy of cervix carcinoma--results of a phase II study].
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 2001 |
Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Pro | 2001 |
Intrarectal application of amifostine for the prevention of radiation-induced rectal injury.
Topics: Adenocarcinoma; Administration, Rectal; Amifostine; Humans; Male; Prostatic Neoplasms; Radiation Dos | 2002 |
Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Pro | 2002 |
Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR-2721.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Amifostine; Combined Modality Therapy; Humans; Middle Aged; | 1992 |
[An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 1. Head and neck tumors].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Child; Clinical Trial | 1985 |
11 other studies available for amifostine anhydrous and Adenocarcinoma
| Article | Year |
|---|---|
Hyperthermic intraperitoneal chemotherapy with cisplatin: Amifostine prevents acute severe renal impairment.
Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy P | 2016 |
An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2009 |
A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury.
Topics: Adenocarcinoma; Administration, Topical; Amifostine; Analysis of Variance; Dose-Response Relationshi | 2002 |
[Minutes of the 23th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Amsterdam, 24-28 October 2004].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Hormonal; Antineo | 2005 |
Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score.
Topics: Adenocarcinoma; Administration, Rectal; Aged; Amifostine; Dose-Response Relationship, Drug; Follow-U | 2008 |
Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid.
Topics: Absorption; Adenocarcinoma; Amifostine; Animals; Carcinoma, Squamous Cell; Female; Liver; Mammary Ne | 1980 |
Modification of stromal radiosensitivity by misonidazole and WR-2721.
Topics: Adenocarcinoma; Amifostine; Animals; Connective Tissue; Dose-Response Relationship, Radiation; Male; | 1983 |
Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient.
Topics: Adenocarcinoma; Amifostine; Ascites; Chromatography, High Pressure Liquid; Disulfides; Half-Life; Hu | 1996 |
Inhibitory effects of WR-2721 and cysteamine on tumor initiation in mammary glands of pregnant rats by radiation.
Topics: Adenocarcinoma; Amifostine; Animals; Body Weight; Cysteamine; Dose-Response Relationship, Radiation; | 2000 |
Rationale for a phase I/II radiation dose-escalation study with concurrent amifostine (Ethyol) and infusional 5-FU chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
Topics: Adenocarcinoma; Amifostine; Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Clin | 2002 |
Stromal radiosensitivity: influence of tumour type on the Tumour Bed Effect assay.
Topics: Adenocarcinoma; Amifostine; Animals; Dose-Response Relationship, Radiation; Mice; Mice, Inbred CBA; | 1985 |